Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

QA 102

Next Previous
Drug Profile

QA 102

Alternative Names: QA-102

Latest Information Update: 17 Jan 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Zhuhai Qiwei Biotechnology
  • Developer Smilebiotek Zhuhai Limited
  • Class Eye disorder therapies; Small molecules
  • Mechanism of Action Bacterial growth inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Dry age-related macular degeneration

Most Recent Events

  • 12 Nov 2024 Smilebiotek Zhuhai Limited completes a phase-II trial in Dry age-related macular degeneration in USA (PO) (NCT05536752)
  • 13 Sep 2022 Zhuhai Qiwei Biotechnology plans a phase II AMEND trial for Dry age-related macular degeneration (In volunteers, In the elderly) in USA (PO, Capsules), in September 2022 (NCT05536752)
  • 06 Jul 2022 Phase-II clinical trials in Dry age-related macular degeneration in USA (PO) (MingMed Biotechnology pipeline, July 2022) (NCT05536752)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top